Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab

Summary

This phase 2 study is designed to evaluate the safety, tolerability and efficacy of allogeneic donor lymphocyte infusions (DLI) combined with the bispecific T cell engager blinatumomab in B-precursor ALL patients who have mixed chimerism (MC) or are MRD-positive after allogeneic SCT and are refractory to at least one MRD- or MC-targeted therapy (i.e. blinatumomab, DLI, tyrosine kinase inhibitors or other agents).

Timeline

Start

2019-06-01

Primary completion

2021-05-31

Completion

2021-11-30

Drugs

Indications